SE9900496D0 - Vaccine formulation - Google Patents

Vaccine formulation

Info

Publication number
SE9900496D0
SE9900496D0 SE9900496A SE9900496A SE9900496D0 SE 9900496 D0 SE9900496 D0 SE 9900496D0 SE 9900496 A SE9900496 A SE 9900496A SE 9900496 A SE9900496 A SE 9900496A SE 9900496 D0 SE9900496 D0 SE 9900496D0
Authority
SE
Sweden
Prior art keywords
sub
formulation
vaccine formulation
sup
adjuvant
Prior art date
Application number
SE9900496A
Other languages
English (en)
Swedish (sv)
Inventor
Ulf Schroeder
Stefan Svenson
Original Assignee
Pharmatrix Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatrix Ab filed Critical Pharmatrix Ab
Priority to SE9900496A priority Critical patent/SE9900496D0/xx
Publication of SE9900496D0 publication Critical patent/SE9900496D0/xx
Priority to EP00903678A priority patent/EP1150713B1/en
Priority to DK00903678T priority patent/DK1150713T3/da
Priority to PCT/EP2000/001038 priority patent/WO2000047224A2/en
Priority to US09/926,002 priority patent/US6890540B1/en
Priority to AU25473/00A priority patent/AU769375B2/en
Priority to DE60019726T priority patent/DE60019726T2/de
Priority to AT00903678T priority patent/ATE293993T1/de
Priority to NZ513129A priority patent/NZ513129A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SE9900496A 1999-02-12 1999-02-12 Vaccine formulation SE9900496D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9900496A SE9900496D0 (sv) 1999-02-12 1999-02-12 Vaccine formulation
EP00903678A EP1150713B1 (en) 1999-02-12 2000-02-09 Vaccine formulation comprising monoglycerides or fatty acids as adjuvant
DK00903678T DK1150713T3 (da) 1999-02-12 2000-02-09 Vaccineformulering der omfatter monoglycerider eller fedtsyrer som adjuvans
PCT/EP2000/001038 WO2000047224A2 (en) 1999-02-12 2000-02-09 Vaccine formulation comprising monoglycerides or fatty acids as adjuvant
US09/926,002 US6890540B1 (en) 1999-02-12 2000-02-09 Vaccine formulation
AU25473/00A AU769375B2 (en) 1999-02-12 2000-02-09 Vaccine formulation
DE60019726T DE60019726T2 (de) 1999-02-12 2000-02-09 Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans
AT00903678T ATE293993T1 (de) 1999-02-12 2000-02-09 Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans
NZ513129A NZ513129A (en) 1999-02-12 2000-02-09 Vaccine formulation active against Mycobacterium tuberculosis bacteria containing a monoglyceride adjuvant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900496A SE9900496D0 (sv) 1999-02-12 1999-02-12 Vaccine formulation

Publications (1)

Publication Number Publication Date
SE9900496D0 true SE9900496D0 (sv) 1999-02-12

Family

ID=20414470

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900496A SE9900496D0 (sv) 1999-02-12 1999-02-12 Vaccine formulation

Country Status (9)

Country Link
US (1) US6890540B1 (xx)
EP (1) EP1150713B1 (xx)
AT (1) ATE293993T1 (xx)
AU (1) AU769375B2 (xx)
DE (1) DE60019726T2 (xx)
DK (1) DK1150713T3 (xx)
NZ (1) NZ513129A (xx)
SE (1) SE9900496D0 (xx)
WO (1) WO2000047224A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047862A1 (en) * 2002-11-26 2004-06-10 Eurocine Ab Novel amine-based adjuvant
US7349378B2 (en) * 2003-02-24 2008-03-25 Toshiba America Research, Inc. Local area network resource manager
EP1725256A4 (en) * 2004-02-18 2008-12-31 Univ Newcastle Res Ass VACCINE FORMULATION FOR ADMINISTRATION TO THE LUNGSSCHLEIMHAUT
JP5159322B2 (ja) * 2005-01-28 2013-03-06 ノース−ウエスト ユニヴァーシティ ワクチンの有効性増強のためのアジュバント
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
ES2531657T3 (es) * 2008-05-01 2015-03-18 Arecor Limited Formulación de una proteína
US9968666B2 (en) 2009-06-12 2018-05-15 Vaccine Technologies, Incorporated Methods and compositions for promoting a cell-mediated immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
WO2010144794A1 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Baculovirus-expressed fusion polypeptide vaccines with enhanced immunogenicity and uses thereof
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
EP3912619A1 (en) 2011-05-11 2021-11-24 Children's Medical Center Corporation Modified biotin-binding protein, fusion proteins thereof and applications
EP2742952A1 (en) 2012-12-17 2014-06-18 Eurocine Vaccines AB Influenza vaccine composition
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
CA2507049A1 (en) 2002-11-26 2004-06-10 Frost Inc. Journal bearing for trolley wheel

Also Published As

Publication number Publication date
NZ513129A (en) 2003-01-31
EP1150713A2 (en) 2001-11-07
DK1150713T3 (da) 2005-08-29
DE60019726D1 (de) 2005-06-02
WO2000047224A2 (en) 2000-08-17
US6890540B1 (en) 2005-05-10
AU769375B2 (en) 2004-01-22
EP1150713B1 (en) 2005-04-27
WO2000047224A3 (en) 2000-12-14
DE60019726T2 (de) 2006-04-27
AU2547300A (en) 2000-08-29
ATE293993T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
SE9900496D0 (sv) Vaccine formulation
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
EP2272531A3 (en) Integration of meningococcal conjugate vaccination
JP2002501033A5 (xx)
SE9600716D0 (sv) Adhesion inhibitors, preparation comprising them and method for producing them
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
NZ333226A (en) Immunstimulating lipid formulation
IL101710A0 (en) Transdermal formulations with increased permeation of the active substances
DK1154792T3 (da) Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans
SE9601158D0 (sv) Method of producing immunogenic products and vaccines
ATE108487T1 (de) Herstellung eines desoxyribonucleosids.
SE0100011D0 (sv) Virus vaccine formulation
CA2365392A1 (en) Vaccine preparation containing fatty acid as a constituent
DE60042776D1 (de) Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen
DE60024326D1 (de) Lipide zur stimulierung der immunreaktion
RU99115191A (ru) Инактивированная вакцина против ку-лихорадки